



Healthcare Weekly News and Deals – February 2nd, 2026

1. Boston Scientific (NYSE: BSX) completes \$600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain

The deal adds Nalu's miniaturized, battery-free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18-year service life. Nalu's system, cleared initially by the FDA in 2019 and later for whole-body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above \$60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. ([Link](#))

2. Laborie acquires JADA System for \$465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio

The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie's comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. ([Link](#))

3. Halozyme Therapeutics acquires Surf Bio for up to \$400M to expand hyperconcentration capabilities in subcutaneous drug delivery

The transaction, closed in late December 2025 and announced January 28, 2026, includes \$300M upfront (subject to adjustments) and up to \$100M in development/regulatory milestones. Surf Bio's platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme's Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. ([Link](#))

4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for \$350 million plus milestones to expand proteomics and multiomics leadership

The acquisition strengthens Illumina's position in the fast-growing proteomics market by integrating SomaLogic's data-driven protein analysis technologies with Illumina's next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. ([Link](#))

Healthcare Weekly News and Deals – February 2nd, 2026

5. Sword Health acquires Kaia Health in \$285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany

The transaction adds Kaia's digital musculoskeletal and pulmonary programs and its coveted position in Germany's reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia's U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. ([Link](#))

6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company

The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise's pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary-care-centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team-based primary care that lowers costs and improves outcomes. ([Link](#))

7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access

The acquisition unites two major digital mental health innovators, combining Spring Health's AI-driven precision care platform with Alma's strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. ([Link](#))

8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management-backed deal to expand neuromodulation and structural heart device capabilities

The acquisition will add Resolution Medical's integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics' presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high-volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. ([Link](#))

Healthcare Weekly News and Deals – February 2nd, 2026

9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities

The acquisition brings BESLER's revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak's existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER's leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. ([Link](#))

10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio

The acquisition advances Nuwellis' move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech's Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech's innovation to market without new sales channels. The transaction, approved by both companies' boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. ([Link](#))

11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform

The deal adds a 50-state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health's TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp's move beyond direct-to-consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. ([Link](#))

12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care

The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W-2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD's virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound's PTSD and complex PTSD services across the U.S. ([Link](#))

Healthcare Weekly News and Deals – February 2nd, 2026

13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage

The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD's team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. ([Link](#))

14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets

The acquisition builds on Choice Health at Home's strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health's broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health's mission to provide accessible, patient-centered care across its seven-state network. ([Link](#))

15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services

The acquisition broadens ncgCARE's community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep's existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep's operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. ([Link](#))

Venture and Other News

1. Vaxcyte prices \$550M public offering at \$50 per share to fund pneumococcal and infectious disease vaccine pipeline

The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of \$550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. ([Link](#))

2. Veradermics and Eikon Therapeutics file for IPOs targeting up to \$181M and \$318M amid biotech market reopening

Veradermics (NYSE: MANE) seeks approximately \$181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to \$318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. ([Link](#))

3. Cellares raises \$257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing

The new funding supports Cellares' global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated "Cell Shuttle" system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. ([Link](#))

Healthcare Weekly News and Deals – February 2nd, 2026

4. **Tenpoint Therapeutics raises \$235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™**

The financing strengthens Tenpoint Therapeutics' position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an \$85 million Series B round and a \$150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company's leadership is focused on driving YUVEZZI™'s successful rollout and expanding access to innovative ophthalmic solutions. ([Link](#))

5. **Breakthru Medicine emerges from stealth with \$60M Series A financing to advance disruptive cancer therapeutics**

The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. ([Link](#))

6. **TRexBio raises \$50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline**

The financing supports TRexBio's ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company's precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. ([Link](#))

7. **Prenosis secures \$20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus \$20M BARDA contract to advance AI diagnostics and therapeutics**

The combined \$40 million will drive Prenosis' development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis' mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. ([Link](#))